TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Flow Capital Corp. (TSXV:FW) (“Flow Capital” or the “Company”) is pleased to announce the successful closing of a US$5.0 million senior note investment in Congruity 360, a leading provider of unstructured data management and risk mitigation solutions. Congruity 360’s Classify360 platform equips organizations with critical capabilities to understand, manage, and secure petabyte-scale unstructured data across cloud, SaaS, and on-premises environments. Its capabilities ...

VANCOUVER, British Columbia, May 29, 2025 (GLOBE NEWSWIRE) -- Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF) (“Coppernico” or the “Company”), is pleased to announce the details of its upcoming virtual Annual General Meeting of Shareholders (the "Meeting"), to be held on Tuesday, June 24, 2025, at 10:00 a.m. Pacific Time, as well as a leadership fireside chat hosted by 3L Capital (the "Webinar"), scheduled for Wednesday, June 4, 2025, at 8:00 a.m. Pacific Time. Annual General Meeting of Shareholders The Me ...

Core Viewpoint - Immunic, Inc. has announced a public offering of pre-funded warrants and series A and B warrants, aiming to raise approximately $65 million initially, with potential total gross proceeds of up to $130 million if all warrants are exercised [1][3]. Group 1: Offering Details - The public offering price for one Pre-Funded Warrant, one Series A Warrant, and one Series B Warrant is set at $0.7499 [1]. - The Pre-Funded Warrants are immediately exercisable, while Series A Warrants can be exercised until December 31, 2025, and Series B Warrants can be exercised starting October 1, 2025, for a period of five years [1]. - The offering is expected to close around June 3, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund clinical trials, operations, and other general corporate purposes [4]. Group 3: Company Overview - Immunic, Inc. is focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, with its lead program, vidofludimus calcium (IMU-838), currently in phase 3 trials for relapsing multiple sclerosis [7]. - Vidofludimus calcium has shown therapeutic activity in earlier trials and combines neuroprotective effects with anti-inflammatory properties [7]. - The company is also developing IMU-856 for gastrointestinal diseases and IMU-381, which is in preclinical testing [7].

Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases [3] - The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, aimed at inhibiting the activity of B cells involved in autoimmune diseases without depleting them [3] - Zenas aims to leverage its experienced leadership and disciplined product candidate acquisition strategy to identify and develop therapies that provide superior clinical benefits to patients [3] Upcoming Events - Zenas BioPharma will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 1:25 p.m. ET [1] - A live webcast and archived replay of the presentation will be available on the company's website under the "Events and Presentations" section [2]

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & Diagnostics Development Symposium (ETDD) ~ LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presentation of a clinical case study of the fir ...

NexGen™ titanium metal powder now qualified for use by BoeingMONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes advanced all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, is pleased to announce today that the Company has received of ...

Immunovant’s new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves’ disease (GD) and a potentially registrational study in Sjögren’s disease (SjD), both expected to start in summer 2025Positive data from first-generation batoclimab trials in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) demonstrated that deeper IgG reductions correlated with improved clini ...

Lantronix Director to Speak on “Out-of-Band Everywhere!”IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge AI Intelligence, today announced that it will do live demos and daily giveaways of its LM4 AI-driven Out-of-Band Management (OOBM) platform at booth 3219 at Cisco Live held June 9–12, 2025, in San Diego. Lantronix, a Cisco Devnet Partner, has the most complete portfolio of out-of-band management con ...

BASEL, Switzerland and LONDON and NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provided a business update. Brepocitinib program progressing well with rapid enrollment in non-infectious uveitis (NIU) Phase 3 study and first patients dosed in cutaneous sarcoidosis (CS) proof-of-concept trial, with readouts expected in the first half of calendar year 2027 and second half of calendar year 2 ...

MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company”), Canada’s leading organic energy drink brand1, will report its financial results for the second quarter ended April 30, 2025, on Thursday, June 12, 2025, before markets open. Management will hold a conference call to discuss its financial results the same day at 10:00 a.m. ET. The conference call will include a Q&A period open exclusively to financial analysts who are invited to participate by using th ...